The compound remains in clinical development rather than FDA approved, positioning it within research peptide markets rather than pharmaceutical distribution channels
Burtness B, Harrington KJ, and Greil R, et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study Lancet 394 (10212) 19151928 PMID: 31679945 67
All treatments are prescribed by licensed providers
The cDNA was amplified in the Opticon Continuous Fluorescent Detector (MJ Research, Waltham, MA, USA) using IQTM SYBR Green supermix (Bio-Rad) and sequence specific primers
Regulatory access depends on the 503A framework